85 results about "Erythrocyte hemolysis" patented technology

A soft polyvinyl chloride plastics for blood transfusion device, such as blood bag, is proportionally prepared from PVC resin, phthalate, trimellitate, citrate, epoxy soybean oil, composite Ca-P stabilizer and silicon oil. Its advantages are no erythrocatalysis, high stability of trimellitate, and low toxin.

The present invention discloses a method for researching oxidation-resisting activity of localized chitosan sulfate. Said invention researches the oxidation-resisting activity of chitosan sulfates (HCTS,TSCTS,SCTS and TCTS) substituted in different position points, and finds that said four kinds of sulfate derivatives have the obvious action for inhibiting superoxide radical and hydroxyl radical, and have strong reducing power. Said four kinds of derivatives also have the strong action for inhibiting hemolysis induced by H2O2. Said invention can be used as basis for developing medicine for resisting senility.

The invention belongs to the technical field of a pharmaceutical, and particularly relates to an red blood cell membrane-coated gelatin-loaded berberine hydrochloride gold nanoparticles, as well as apreparation method and application thereof. The RBCM-BH-GNPs prepared through the method is uniform in particle size distribution and favorable in stability, and shows a remarkable shell-core structure; a single-layer erythrocyte membrane coats spherical BH-GNPs. The RBCM-BH-GNPs cannot cause erythrocytes hemolysis or agglutination in vitro, and can be used for intravenous injection. In addition,the RBCM-BH-GNPs prepared through the invention has a remarkable in vitro sustained release effect on BH in vitro and the sustained release effect is superior to the BH-GNPs, the RBCM-BH-GNPs solves the problems of hemangiectasis, fall of blood pressure, heart inhibition and side reaction caused by excessive plasma drug peak concentration since BH common injection is short of slow release, and provides an idea for expanding clinical application of the BH and developing new traditional Chinese medicine preparations of the BH.

The present invention relates to a method for detecting substances specifically inhibiting a type III secretion mechanism and functions of the type III secretory proteins, within short time and large amounts thereof, without depending upon animal infectious experiments. Namely it relates to the method for detection of a type III secretory mechanism inhibitor comprising mixing a bacterium having the type III secretory mechanism and an erythrocyte suspension, adding the type III secretory mechanism inhibitor thereto, and detecting changes in the thus formed hemolytic activity. The method for detecting substances can be treated large amount of samples within short time by exhibiting the substances inhibiting the type III secretion mechanism or the functions of the type III secretory proteins as numerical index of the hemolytic activity of erythrocytes. Consequently, the present invention is useful for development of drugs.

The invention relates to application of three kinds of oroxin in preparing a drug for resisting staphylococcus aureus infection. The staphylococcus aureus infection resistance of three kinds of oroxin can be proved by virtue of a sheep red blood cell haemolysis test, molecular dynamics simulation and a human pulmonary epithelial cell (A549) injury protective test. Compared with treatment by antibiotics, treatment by using three kinds of oroxin has the characteristics of no drug resistance and high cure rate, so that the three kinds of oroxin can be used in development of new drugs, and has an important meaning to drug target confirmation.

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic / metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

The invention provides a screening method for erythrocyte osmotic fragility, which comprises the following steps: S1, test solutions of the erythrocyte osmotic fragility are added into an enzyme plate and preheated at a temperature of 37 to 40 DEG C for 1-2 minutes; S2, 5-10 Mu l of anticoagulant whole blood to be measured is added into holding sample holes of partial areas of the enzyme plate, and then the test solution of the erythrocyte osmotic fragility and the anticoagulant whole blood are mixed evenly; S3, test solutions for stopping erythrocyte hemolysis are added into the partial areas filled with the anticoagulant whole blood to be measured, all solutions are mixed evenly and centrifugation is carried out; S4, the supernatant is removed and placed in the holding sample holes of the other partial areas of the enzyme plate; S5, erythrocyte hemolysis solutions are added into the base solution, and all solutions are mixed evenly; S6, after the hemolysis process is finished, colorimetry is carried out between the solution to be measured of the partial areas filled with the erythrocyte hemolysis test solution and the solution of the other partial areas not filled with the erythrocyte hemolysis test solution. With the advantages of simplicity, trace amounts, fast speed and large samples, the screening method for the erythrocyte osmotic fragility further has the advantages that the screening workload can be reduced, the screening can be completed fast and accurately, the reproducible results can be obtained and the experimental results can be automatically calculated.

An extract of the abalone mushroom for improving immunity, preventing diseases and taking care of human health is composed of the extract P0.5a containing polyose (82.64%) and protein (0.63%) and the extract P0.5b-1 containing polyose (45.48%) and protein (12.63%). Its extracting method is also disclosed.

The invention belongs to the technical field of pharmaceutical chemistry, and discloses an amide aromatic phenol antibacterial peptide analogue with drug-resistance bacteria resistant activity and without obvious toxicity and a preparation method thereof. The target product is obtained by 3-4 reaction steps, and the main structure of the product is shown as follows. In-vitro antibacterial activityexperiments prove that most of the series of compounds have excellent activity on Gram-positive staphylococcus aureus and enterococcus faecalis, Gram-negative Escherichia coli and stenotrophomonas maltophilia, and the compounds have excellent broad spectrum antibacterial activity; moreover, in-vitro red cell hemolytic data is low in toxicity and has excellent selectivity. One part of the compounds also have excellent antibacterial activity on 'superbacteria' comprising drug-resistant methicillin staphylococcus aureus (MRSA), clinical strains producing enzymes NDM-1 and KPC-2 and the like. Therefore, the series of compounds are expected to serve as novel antibacterial candidate drugs.